Translating The Foreign Corrupt Practices Act Into Practice: U.S. DoJ/SEC Offer Pragmatic Enforcement Guide
This article was originally published in PharmAsia News
Executive Summary
The FCPA resource guide gives examples of cases the DoJ and SEC have decided not to prosecute and describes the hallmarks of an effective compliance program; PhRMA, GPhA among groups that were asking for more clarity.
You may also be interested in...
Case Studies: Several Patent And Registration Litigations Highlight What Not To Do In China
BEIJING - It is a common refrain now for companies that do business in China that the country's intellectual property protection regime, while not perfect, is improving. But a recent conference on regulatory and legal issues in Beijing provided some discouraging examples about the challenges companies face in dealing with patent litigation and import certification in China
J&J Takes The Lead In Settling SEC/DoJ Foreign Corrupt Practices Act Probe
Johnson & Johnson agreed to pay $70 million to resolve charges by the Securities and Exchange Commission and the Department of Justice that the company bribed doctors in several European countries to order or prescribe its products in violation of the Foreign Corrupt Practices Act
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.